Manns M, Bergquist A, Karlsen T, Levy C, Muir A, Ponsioen C
Nat Rev Dis Primers. 2025; 11(1):17.
PMID: 40082445
DOI: 10.1038/s41572-025-00600-x.
Cancado G, Hirschfield G
Hepatol Commun. 2025; 8(12).
PMID: 39774274
PMC: 11567710.
DOI: 10.1097/HC9.0000000000000590.
Helmke S, Kittelson J, Imperial J, McRae M, Everson G
Gastro Hep Adv. 2024; 3(7):944-953.
PMID: 39286620
PMC: 11403427.
DOI: 10.1016/j.gastha.2024.07.005.
Boraschi P, Mazzantini V, Donati F, Coco B, Vianello B, Pinna A
Eur J Radiol Open. 2024; 13:100595.
PMID: 39206437
PMC: 11357777.
DOI: 10.1016/j.ejro.2024.100595.
Hussain N, Ma C, Hirschfield G, Walmsley M, Hanford P, Vesterhus M
BMJ Open. 2024; 14(6):e080143.
PMID: 38926149
PMC: 11216047.
DOI: 10.1136/bmjopen-2023-080143.
Primary Sclerosing Cholangitis: Diagnostic Criteria.
Cazzagon N, Sarcognato S, Catanzaro E, Bonaiuto E, Peviani M, Pezzato F
Tomography. 2024; 10(1):47-65.
PMID: 38250951
PMC: 10820917.
DOI: 10.3390/tomography10010005.
Interobserver agreement and prognostic value of image-based scoring systems in patients with primary sclerosing cholangitis.
Grave E, Loehfelm T, Corwin M, Zepeda J, Bath H, Dhaliwal S
Abdom Radiol (NY). 2023; 49(1):60-68.
PMID: 37831167
DOI: 10.1007/s00261-023-04051-4.
Molecular magnetic resonance imaging of liver inflammation using an oxidatively activated probe.
Clavijo Jordan V, Sojoodi M, Shroff S, Gonzalez Pagan P, Barrett S, Wellen J
JHEP Rep. 2023; 5(10):100850.
PMID: 37818152
PMC: 10561122.
DOI: 10.1016/j.jhepr.2023.100850.
EUS-guided percutaneous liver biopsy: A prospective randomized clinical trial.
Ali A, Nallapeta N, Yousaf M, Petroski G, Sharma N, Rao D
Endosc Ultrasound. 2023; 12(3):334-341.
PMID: 37693114
PMC: 10437149.
DOI: 10.1097/eus.0000000000000010.
A composite score using quantitative magnetic resonance cholangiopancreatography predicts clinical outcomes in primary sclerosing cholangitis.
Vuppalanchi R, Are V, Telford A, Young L, Mouchti S, Ferreira C
JHEP Rep. 2023; 5(10):100834.
PMID: 37663118
PMC: 10472223.
DOI: 10.1016/j.jhepr.2023.100834.
Oxidative stress-related markers as prognostic factors for patients with primary sclerosing cholangitis in Japan.
Oyama A, Takaki A, Adachi T, Wada N, Takeuchi Y, Onishi H
Hepatol Int. 2023; 17(5):1215-1224.
PMID: 37493884
PMC: 10522747.
DOI: 10.1007/s12072-023-10557-2.
The Many Faces of Primary Sclerosing Cholangitis: Controversy Abounds.
Wentworth B, Khot R, Caldwell S
Dig Dis Sci. 2023; 68(9):3514-3526.
PMID: 37358638
DOI: 10.1007/s10620-023-08003-2.
Protective potential of the gallbladder in primary sclerosing cholangitis.
Cazzagon N, Gonzalez-Sanchez E, El-Mourabit H, Wendum D, Rainteau D, Humbert L
JHEP Rep. 2023; 5(4):100649.
PMID: 36923239
PMC: 10009728.
DOI: 10.1016/j.jhepr.2022.100649.
PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis.
Trauner M, Chung C, Sterling K, Liu X, Lu X, Xu J
BMC Gastroenterol. 2023; 23(1):75.
PMID: 36922785
PMC: 10015541.
DOI: 10.1186/s12876-023-02653-2.
Primary sclerosing cholangitis-A long night's journey into day.
Chapman R
Clin Liver Dis (Hoboken). 2022; 20(Suppl 1):21-32.
PMID: 36518789
PMC: 9742753.
DOI: 10.1002/cld.1264.
Artificial intelligence for precision medicine in autoimmune liver disease.
Gerussi A, Scaravaglio M, Cristoferi L, Verda D, Milani C, De Bernardi E
Front Immunol. 2022; 13:966329.
PMID: 36439097
PMC: 9691668.
DOI: 10.3389/fimmu.2022.966329.
The microbiota and the gut-liver axis in primary sclerosing cholangitis.
Hov J, Karlsen T
Nat Rev Gastroenterol Hepatol. 2022; 20(3):135-154.
PMID: 36352157
DOI: 10.1038/s41575-022-00690-y.
Role of ductular reaction and ductular-canalicular junctions in identifying severe primary biliary cholangitis.
Overi D, Carpino G, Cristoferi L, Onori P, Kennedy L, Francis H
JHEP Rep. 2022; 4(11):100556.
PMID: 36267871
PMC: 9576897.
DOI: 10.1016/j.jhepr.2022.100556.
Primary sclerosing cholangitis: review for radiologists.
Morgan M, Khot R, Sundaram K, Ludwig D, Nair R, Mittal P
Abdom Radiol (NY). 2022; 48(1):136-150.
PMID: 36063181
PMC: 9852001.
DOI: 10.1007/s00261-022-03655-6.
Quality of life (QoL) for people with primary sclerosing cholangitis (PSC): a pragmatic strategy for identifying relevant QoL issues for rare disease.
Marcus E, Stone P, Thorburn D, Walmsley M, Vivat B
J Patient Rep Outcomes. 2022; 6(1):76.
PMID: 35840704
PMC: 9287498.
DOI: 10.1186/s41687-022-00484-5.
